Cite
123P Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China.
MLA
Wang, S., and B. Han. “123P Long Term Survival Analysis of Osimertinib in Stage IV NSCLC Patients Harbored Acquired EGFR T790M Mutation: A Real-Word Study in China.” Annals of Oncology, vol. 30, Apr. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz063.021.
APA
Wang, S., & Han, B. (2019). 123P Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China. Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz063.021
Chicago
Wang, S, and B Han. 2019. “123P Long Term Survival Analysis of Osimertinib in Stage IV NSCLC Patients Harbored Acquired EGFR T790M Mutation: A Real-Word Study in China.” Annals of Oncology 30 (April): N.PAG. doi:10.1093/annonc/mdz063.021.